Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 191.23 USD 0.55% Market Closed
Updated: Aug 14, 2024
Have any thoughts about
Abbvie Inc?
Write Note

Profitability Summary

Abbvie Inc's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Abbvie Inc

Revenue
55B USD
Cost of Revenue
-18.3B USD
Gross Profit
36.7B USD
Operating Expenses
-20.6B USD
Operating Income
16B USD
Other Expenses
-10.7B USD
Net Income
5.3B USD

Margins Comparison
Abbvie Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Abbvie Inc
NYSE:ABBV
337.7B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
173.8B USD
63%
20%
10%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
128.7B USD
87%
31%
32%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.6B USD
86%
41%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
149.2B AUD
52%
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
92.2B USD
77%
37%
4%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Palatin Technologies Inc
LSE:0KF3
37B USD
97%
-555%
-557%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.3B USD
87%
4%
-3%
US
Moderna Inc
NASDAQ:MRNA
31.8B USD
40%
-85%
-116%
Country US
Market Cap 337.7B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 173.8B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 128.7B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 120.6B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 149.2B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 92.2B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 37B USD
Gross Margin
97%
Operating Margin
-555%
Net Margin
-557%
Country US
Market Cap 34.3B USD
Gross Margin
87%
Operating Margin
4%
Net Margin
-3%
Country US
Market Cap 31.8B USD
Gross Margin
40%
Operating Margin
-85%
Net Margin
-116%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Abbvie Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Abbvie Inc
NYSE:ABBV
337.7B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
173.8B USD
49%
3%
9%
8%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
128.7B USD
17%
13%
14%
17%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.6B USD
-3%
-2%
25%
-84%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
149.2B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
92.2B USD
5%
2%
23%
13%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Palatin Technologies Inc
LSE:0KF3
37B USD
-588%
-178%
-395%
-5 705%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
34.3B USD
35%
-2%
4%
9%
US
Moderna Inc
NASDAQ:MRNA
31.8B USD
-41%
-31%
-27%
-58%
Country US
Market Cap 337.7B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 173.8B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 128.7B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 120.6B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 149.2B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 92.2B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 37B USD
ROE
-588%
ROA
-178%
ROCE
-395%
ROIC
-5 705%
Country US
Market Cap 34.3B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%
Country US
Market Cap 31.8B USD
ROE
-41%
ROA
-31%
ROCE
-27%
ROIC
-58%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top